Literature DB >> 11090138

Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex.

T R Fouts1, R Tuskan, K Godfrey, M Reitz, D Hone, G K Lewis, A L DeVico.   

Abstract

The infection of CD4(+) host cells by human immunodeficiency virus type 1 (HIV-1) is initiated by a temporal progression of interactions between specific cell surface receptors and the viral envelope protein, gp120. These interactions produce a number of intermediate structures with distinct conformational, functional, and antigenic features that may provide important targets for therapeutic and vaccination strategies against HIV infection. One such intermediate, the gp120-CD4 complex, arises from the interaction of gp120 with the CD4 receptor and enables interactions with specific coreceptors needed for viral entry. gp120-CD4 complexes are thus promising targets for anti-HIV vaccines and therapies. The development of such strategies would be greatly facilitated by a means to produce the gp120-CD4 complexes in a wide variety of contexts. Accordingly, we have developed single-chain polypeptide analogues that accurately replicate structural, functional, and antigenic features of the gp120-CD4 complex. One analogue (FLSC) consists of full-length HIV-1BaL gp120 and the D1D2 domains of CD4 joined by a 20-amino-acid linker. The second analogue (TcSC) contains a truncated form of the gp120 lacking portions of the C1, C5, V1, and V2 domains. Both molecules exhibited increased exposure of epitopes in the gp120 coreceptor-binding site but did not present epitopes of either gp120 or CD4 responsible for complex formation. Further, the FLSC and TcSC analogues bound specifically to CCR5 (R5) and blocked R5 virus infection. Thus, these single-chain chimeric molecules represent the first generation of soluble recombinant proteins that mimic the gp120-CD4 complex intermediate that arises during HIV replication.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090138      PMCID: PMC112421          DOI: 10.1128/jvi.74.24.11427-11436.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses.

Authors:  M A Vodicka; W C Goh; L I Wu; M E Rogel; S R Bartz; V L Schweickart; C J Raport; M Emerman
Journal:  Virology       Date:  1997-06-23       Impact factor: 3.616

2.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

Review 3.  HIV entry and its inhibition.

Authors:  D C Chan; P S Kim
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

4.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

5.  Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  S A Jeffs; J McKeating; S Lewis; H Craft; D Biram; P E Stephens; R L Brady
Journal:  J Gen Virol       Date:  1996-07       Impact factor: 3.891

6.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

Authors:  L Wu; N P Gerard; R Wyatt; H Choe; C Parolin; N Ruffing; A Borsetti; A A Cardoso; E Desjardin; W Newman; C Gerard; J Sodroski
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

7.  Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein.

Authors:  R Wyatt; E Desjardin; U Olshevsky; C Nixon; J Binley; V Olshevsky; J Sodroski
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

Review 8.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

Authors:  R Wyatt; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

9.  Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates.

Authors:  A Devico; A Silver; A M Thronton; M G Sarngadharan; R Pal
Journal:  Virology       Date:  1996-04-01       Impact factor: 3.616

10.  CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.

Authors:  N Sullivan; Y Sun; Q Sattentau; M Thali; D Wu; G Denisova; J Gershoni; J Robinson; J Moore; J Sodroski
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

View more
  71 in total

1.  Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Authors:  Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

2.  Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.

Authors:  Hua-Xin Liao; S Munir Alam; John R Mascola; James Robinson; Benjiang Ma; David C Montefiori; Maria Rhein; Laura L Sutherland; Richard Scearce; Barton F Haynes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

3.  Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Authors:  Mohammad M Sajadi; George K Lewis; Michael S Seaman; Yongjun Guan; Robert R Redfield; Anthony L DeVico
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies.

Authors:  Gilad Kaplan; Anna Roitburd-Berman; George K Lewis; Jonathan M Gershoni
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

5.  Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses.

Authors:  Mohammad Mohseni Sajadi; Amir Dashti; Zahra Rikhtegaran Tehrani; William D Tolbert; Michael S Seaman; Xin Ouyang; Neelakshi Gohain; Marzena Pazgier; Dongkyoon Kim; Guy Cavet; Jean Yared; Robert R Redfield; George K Lewis; Anthony L DeVico
Journal:  Cell       Date:  2018-05-03       Impact factor: 41.582

6.  The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.

Authors:  Abraham Pinter; William J Honnen; Paul D'Agostino; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 7.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

8.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  HIV Vaccines: Biological and Clinical Considerations.

Authors:  M. Patricia D'Souza; Mary A. Allen; Margaret I. Johnston
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

10.  Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers.

Authors:  Weizao Chen; Zhongyu Zhu; Yang Feng; Dimiter S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.